Incretin Agonists: Safety, Optimization and Support

This week, we address a hot and controversial topic in medicine: weight loss pharmaceuticals.  Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptides (GIP) agonists are gaining popularity for their use in treating type 2 diabetes and, in some cases, obesity. These medications stimulate insulin secretion and are shown to increase weight loss and improve blood pressure. However, significant gastrointestinal and other rare but concerning side effects make these medications controversial. Patients often also gain back much of the lost weight when these medications are stopped. Our guest this episode is Christina Robins, MD, who has a successful clinic called RevitaLife, which blends family medicine, women's health care, antiaging medicine and medical weight loss, among other services. Dr. Robins has long been using GLP-1 agonists with her patients, and she joined James to share her strategies for supporting patients using those medications in combination with nutraceutical support. Listen to the full conversation to learn about the following: Lifestyle and nutraceutical support before, during and after the use of weight-loss medications How to prevent connective tissue and muscle loss during weight loss FDA approval for weight loss and type 2 diabetes drugs Appropriate uses for these medications and potential off-label uses And much, much more!

There are no comments yet.

Please log in to write the first comment.